Zobrazeno 1 - 10
of 730
pro vyhledávání: '"Chia-chi Lin"'
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Mei‐Lang Kung, Tai‐Hua Yang, Chia‐Chi Lin, Jia‐Yun Ho, Tzu‐Chi Hung, Chih‐Hsiang Chang, Kuan‐Wen Huang, Chien‐Chin Chen, Yun‐Wen Chen
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 949-962 (2024)
Abstract Background Non‐alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, which is com
Externí odkaz:
https://doaj.org/article/fb556a7924ad44db8252e7b91d13e836
Autor:
Toshihiko Doi, David Tai, Dong-Wan Kim, F Stephen Hodi, Sofie Wilgenhof, Catherine Sabatos-Peyton, Giuseppe Curigliano, Chia-Chi Lin, Armando Santoro, Alexandros Xyrafas, Nicolas Mach, Sebastian Szpakowski, Shripad Chitnis, Sabine Gutzwiller, Alessandro Pastore
Publikováno v:
BMJ Open, Vol 14, Iss 8 (2024)
Objective This study evaluates the safety/efficacy of sabatolimab plus spartalizumab in patients with melanoma or non-small cell lung cancer (NSCLC).Design, setting and participants This is a phase 1–1b/2, open-label, multinational, multicentre stu
Externí odkaz:
https://doaj.org/article/e226d4538acb4bd0bc0fcd5648207830
Publikováno v:
Journal of International Medical Research, Vol 52 (2024)
Objective To investigate the suicide risk factors among caregivers of individuals with depression who may develop suicidal ideation due to the ongoing challenges of managing the patient's mood fluctuations. Methods This cross-sectional study enrolled
Externí odkaz:
https://doaj.org/article/cae8785ab78949abb869ad68359a7465
Autor:
Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, Ruoh-Fang Yen, Chia-Chi Lin, Muh-Hwa Yang, Chueh-Chuan Yen, Wu-Chou Su, Chia-Jui Yen, Yi-Fang Chang, Ming-Fang Wu, Youngsen Yang, Chen-Yuan Lin, Wen-Chi Yang, Hui-Ching Wang, Cheng-Yuan Li, Yin-Yu Ho, Yao-Yu Chang, Chieh-Shan Wu, Hsiu-Cheng Hsu, Kuang-Hua Chen, Yenlin Huang, Chih-Jung Chen, Pei-Ju Chuang, Yung-Chi Lai, Yu-Yi Huang, Neng-Chuan Tseng, Yi-Ting Huang, Chia-Yu Chu, John Wen-Cheng Chang
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 1, Pp 7-15 (2024)
Melanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of the clinical
Externí odkaz:
https://doaj.org/article/04854f0faec04d159246a6f4a85d5aa9
Autor:
Jhe‐Cyuan Guo, Chia‐Lang Hsu, Min‐Shu Hsieh, Chia‐Chi Lin, Ta‐Chen Huang, Hung‐Yang Kuo, Yu‐Yun Shao, Chih‐Hung Hsu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 22, Pp 2216-2221 (2023)
Abstract Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a
Externí odkaz:
https://doaj.org/article/de78700a496347f09d35ff706fccb537
Autor:
Thomas Yau, Ignacio Garrido-Laguna, Pierre-Eric Juif, Markus Joerger, Anna Spreafico, Todd M Bauer, Chia-Chi Lin, Armando Santoro, Richard Greil, Helen Evans, Marc Pelletier, Toshikiko Doi, Maria-Elisabeth Goebeler, Viviana Cremasco, Marie Luise Hütter-Krönke, Antonella Perotti, Darlene Lu, Louise Barys, Claire Fabre
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.Methods Patients received
Externí odkaz:
https://doaj.org/article/e339d08408a2485f90c3737b27e2f7e9
Autor:
Jameel Muzaffar, Tae Min Kim, Julie Brahmer, Dirk G Brockstedt, Chia-Chi Lin, Michael Chisamore, Ki Hyeong Lee, Paul D Kassner, Nuttapong Ngamphaiboon, William Ho, Nicole Nasrah, Pratibha Desai, Yin-Hsun Feng, Shang-Yin Wu, Rakesh Kumar Goyal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/bd8985e88135407b9ef78e59280fb9c0
Autor:
Wei‐Li Ma, Chia‐Chi Lin, Feng‐Ming Hsu, Jang‐Ming Lee, Jin‐Shing Chen, Yen‐Lin Huang, Yih‐Leong Chang, Chin‐Hao Chang, James Chih‐Hsin Yang
Publikováno v:
Cancer Medicine, Vol 11, Iss 18, Pp 3445-3456 (2022)
Abstract Background Front‐line platinum‐base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front‐l
Externí odkaz:
https://doaj.org/article/e574cac37ef049b4843c2bd862c774dd
Autor:
Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100499- (2023)
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than
Externí odkaz:
https://doaj.org/article/c09913d79c7448e094d8c942679bfbff